The Global Biosimulation Market size is expected to reach $11.16 billion by 2031, rising at a market growth of 16.7% CAGR during the forecast period.
The North America segment acquired 47% revenue share in the market in 2023. This preeminence can be ascribed to the region's sophisticated healthcare infrastructure, substantial investments in pharmaceutical and biotechnology research, and the prompt integration of innovative technologies. The presence of prominent industry stakeholders, in conjunction with substantial governmental support for pharmaceutical development and personalized medicine, has significantly accelerated market expansion in this region.
Advancements in computational modeling and simulation techniques have transformed this by significantly enhancing the accuracy and efficiency of models through the integration of artificial intelligence (AI) and machine learning (ML). These technologies enable researchers to analyze vast datasets, uncover patterns, and predict biological behaviors critical for drug discovery and development. Hence, these advancements will aid in the expansion of the market.
Additionally, Minimizing clinical trial failures is essential for pharmaceutical companies due to drug development's high costs and time. They offers a powerful solution by predicting trial outcomes and identifying potential risks before trials begin. Through advanced computational modeling, researchers can simulate drug interactions and biological responses in virtual environments, allowing them to refine trial designs and mitigate risks. Thus, as its applications expand, this is becoming integral to modern drug development, driving efficiency and innovation in the pharmaceutical industry.
Moreover, The COVID-19 pandemic presented initial challenges to this market, as disruptions to clinical trials and research activities delayed data collection and hindered the development of accurate models. With restrictions in place and resources redirected toward immediate pandemic response efforts, many pharmaceutical and biotechnology companies had to scale back investments in this for non-COVID-related projects. Additionally, economic uncertainties and budget constraints, particularly for smaller organizations, further slowed the adoption of these technologies in the early stages of the pandemic. Thus, the pandemic had an overall positive impact on the market.
However, these platforms and tools often require substantial financial investment for initial software acquisition and the accompanying infrastructure needed for seamless deployment. These tools are designed to simulate complex biological processes, which demand advanced algorithms, robust computational power, and regular updates to remain effective. Hence, without strategies to make these solutions more affordable or accessible, this cost barrier will continue to restrict the adoption of these technologies across broader segments of the healthcare and research industries.
The leading players in the market are competing with diverse innovative offerings to remain competitive in the market. The above illustration shows the percentage of revenue shared by some of the leading companies in the market. The leading players of the market are adopting various strategies in order to cater demand coming from the different industries. The key developmental strategies in the market are Acquisitions, and Partnerships & Collaborations.
The North America segment acquired 47% revenue share in the market in 2023. This preeminence can be ascribed to the region's sophisticated healthcare infrastructure, substantial investments in pharmaceutical and biotechnology research, and the prompt integration of innovative technologies. The presence of prominent industry stakeholders, in conjunction with substantial governmental support for pharmaceutical development and personalized medicine, has significantly accelerated market expansion in this region.
Advancements in computational modeling and simulation techniques have transformed this by significantly enhancing the accuracy and efficiency of models through the integration of artificial intelligence (AI) and machine learning (ML). These technologies enable researchers to analyze vast datasets, uncover patterns, and predict biological behaviors critical for drug discovery and development. Hence, these advancements will aid in the expansion of the market.
Additionally, Minimizing clinical trial failures is essential for pharmaceutical companies due to drug development's high costs and time. They offers a powerful solution by predicting trial outcomes and identifying potential risks before trials begin. Through advanced computational modeling, researchers can simulate drug interactions and biological responses in virtual environments, allowing them to refine trial designs and mitigate risks. Thus, as its applications expand, this is becoming integral to modern drug development, driving efficiency and innovation in the pharmaceutical industry.
Moreover, The COVID-19 pandemic presented initial challenges to this market, as disruptions to clinical trials and research activities delayed data collection and hindered the development of accurate models. With restrictions in place and resources redirected toward immediate pandemic response efforts, many pharmaceutical and biotechnology companies had to scale back investments in this for non-COVID-related projects. Additionally, economic uncertainties and budget constraints, particularly for smaller organizations, further slowed the adoption of these technologies in the early stages of the pandemic. Thus, the pandemic had an overall positive impact on the market.
However, these platforms and tools often require substantial financial investment for initial software acquisition and the accompanying infrastructure needed for seamless deployment. These tools are designed to simulate complex biological processes, which demand advanced algorithms, robust computational power, and regular updates to remain effective. Hence, without strategies to make these solutions more affordable or accessible, this cost barrier will continue to restrict the adoption of these technologies across broader segments of the healthcare and research industries.
The leading players in the market are competing with diverse innovative offerings to remain competitive in the market. The above illustration shows the percentage of revenue shared by some of the leading companies in the market. The leading players of the market are adopting various strategies in order to cater demand coming from the different industries. The key developmental strategies in the market are Acquisitions, and Partnerships & Collaborations.
Driving and Restraining Factors
Drivers- Advancements In Computational Modeling And Simulation Techniques
- Growing Need For Minimizing Clinical Trial Failures
- Rising Prevalence Of Chronic Diseases
- High Cost Of Software And Implementation
- Complexity Of Biosimulation Models
- Increasing Focus On Personalized Medicine
- Growing Collaboration Between Academia And Industry
- Regulatory And Compliance Challenges
- Data Quality And Integration Issues
End Use Outlook
By end use, the market is classified into life sciences companies, academic research institutions, and others. The academic research institutions segment procured 32% revenue share in the market in 2023. Academic institutions are instrumental in the advancement of these technologies through the execution of foundational research and the development of innovative models for the examination of biological systems. These institutions often collaborate with industry players to refine and validate simulation tools, making them a key stakeholder in this ecosystem.Product Outlook
Based on product, the market is bifurcated into software and services. The services segment procured 40% revenue share in the market in 2023. The growth of the services segment is fueled by the rising complexity of drug development processes and the increasing reliance on expert consulting and technical support. These services assist organizations in navigating these challenges by offering model customization, validation, and training.Pricing Model Outlook
On the basis of pricing model, the market is divided into license-based model, subscription-based model, service-based model, and pay per use model. The service-based model segment witnessed 19% revenue share in the market in 2023. This model gives organizations access to this expertise and infrastructure as needed, allowing them to avoid high upfront costs associated with purchasing software or building in-house capabilities. The flexibility of the service-based model is especially appealing to smaller companies and start-ups, which may lack the resources to invest in standalone software.
Application Outlook
On the basis of application, the market is classified into drug discovery & development, disease modeling, and others. The drug discovery & development segment acquired 55% revenue share in the market in 2023. These tools have revolutionized drug discovery by enabling researchers to model complex biological systems, predict drug interactions, and optimize formulations before conducting physical experiments. This significantly reduces the time and cost of bringing new drugs to market.Deployment Model Outlook
Based on deployment model, the market is segmented into cloud-based, on-premises, and hybrid model. The on-premises segment acquired 35% revenue share in the market in 2023. Organizations handling sensitive proprietary data or operating in regions with strict data privacy laws often prefer on-premises solutions to retain complete control over their biosimulation processes. For example, large pharmaceutical companies like Novartis rely on on-premises biosimulation tools to manage proprietary drug development data, ensuring adherence to industry-specific standards like HIPAA and GDPR.Therapeutic Area Outlook
By therapeutic area, the market is divided into oncology, cardiovascular disease, infectious disease, neurological disorders, and others. The cardiovascular disease segment garnered 26% revenue share in the market in 2023. They plays a crucial role in designing and optimizing therapies for these complex disorders by modeling drug effects on the cardiovascular system. For instance, this was pivotal in developing novel anticoagulants like apixaban (Eliquis), which helped predict safety profiles and efficacy in preventing stroke in patients with atrial fibrillation.Regional Outlook
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Europe segment recorded 26% revenue share in the market in 2023. European countries, particularly Germany, the United Kingdom, and France, have witnessed substantial investments in these tools to enhance drug discovery and optimize clinical trial designs. The region's emphasis on sustainability and precision medicine, along with supportive policies for digital transformation in healthcare, has accelerated the adoption of these technologies.Recent Strategies Deployed in the Market
- Oct-2024: Certara, Inc. completed the acquisition Chemaxon, a provider of in-silico research software for life sciences, to integrate precision chemistry tools into Certara’s biosimulation platforms. Chemaxon, known for products like JChem Engines, complements Certara’s Simcyp PBPK Simulator and Certara.AI. The collaboration aims to improve prediction accuracy in drug discovery, especially for precision medicine therapies, while enhancing scientific innovation and productivity in the life sciences sector.
- Aug-2024: Certara, Inc. launched Phoenix™ version 8.5, an advanced PK/PD and toxicokinetic modeling platform used globally by pharmaceutical companies and regulators like the U.S. FDA. Enhancements include centralized cloud sign-in, improved reporting customization, and refined non-linear mixed effects modeling (NLME) tools. These updates streamline workflows, improve precision, and enhance data interpretation, aligning with Certara’s mission to accelerate drug development and regulatory review processes.
- Jun-2024: Simulations Plus, Inc. acquired Pro-ficiency, a provider of AI-powered simulation tools for clinical and commercial drug development, for $100 million. This acquisition broadens Simulations Plus’s capabilities to cover pre-clinical to commercialization stages, integrating clinical trial operations and training. Pro-ficiency, previously backed by QHP Capital, specializes in immersive simulation learning and data-driven insights, complementing Simulations Plus's biosimulation expertise and expanding its market opportunities.
- May-2024: Simulations Plus, Inc. launched GastroPlus® X (GPX™), an advanced PBPK/PBBM platform. GPX introduces machine learning, streamlined workflows, and intuitive design for applications like drug absorption and first-in-human outcomes. The platform supports regulatory interactions, aligning with initiatives like the FDA’s Quantitative Medicine Center of Excellence. The launch underscores Simulations Plus's commitment to innovation and global market expansion.
- Apr-2024: Certara, Inc. launched Certara Cloud, the unifying platform that integrates its many scientific software solutions. Certara Cloud enhances the customer experience for clients that utilize multiple Certara products. Additionally, it enables Certara to both integrate with and launch interoperable software solutions that span Certara's customers’ workflows from discovery to submission.
List of Key Companies Profiled
- Certara, Inc.
- Dassault Systemes SE
- Advanced Chemistry Development, Inc.
- Genedata AG (Danaher Corporation)
- Instem Group of Companies
- Chemical Computing Group ULC
- Simulations Plus, Inc.
- Schrodinger, Inc.
- PPD, Inc. (Thermo Fisher Scientific, Inc.)
- Physiomics Plc
Market Report Segmentation
By Product- Software
- Molecular Modeling & Simulation Software
- Clinical Trial Design Software
- PK/PD Modeling and Simulation Software
- Pbpk Modeling and Simulation Software
- Toxicity Prediction Software
- Other Software Type
- Services
- Contract Services
- Consulting
- Other Services Type
- License-based Model
- Subscription-based Model
- Service-based Model
- Pay Per Use Model
- Life Sciences Companies
- Academic Research Institutions
- Other End Use
- Drug Discovery & Development
- Disease Modeling
- Other Application
- Cloud-based
- On-premises
- Hybrid Model
- Oncology
- Cardiovascular Disease
- Infectious Disease
- Neurological Disorders
- Other Therapeutic Area
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. Global Biosimulation Market by Product
Chapter 6. Global Biosimulation Market by Pricing Model
Chapter 7. Global Biosimulation Market by End Use
Chapter 8. Global Biosimulation Market by Application
Chapter 9. Global Biosimulation Market by Deployment Model
Chapter 10. Global Biosimulation Market by Therapeutic Area
Chapter 11. Global Biosimulation Market by Region
Chapter 12. Company Profiles
Companies Mentioned
- Certara, Inc.
- Dassault Systemes SE
- Advanced Chemistry Development, Inc.
- Genedata AG (Danaher Corporation)
- Instem Group of Companies
- Chemical Computing Group ULC
- Simulations Plus, Inc.
- Schrodinger, Inc.
- PPD, Inc. (Thermo Fisher Scientific, Inc.)
- Physiomics Plc
Methodology
LOADING...
